WO2024260434 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR)
National phase entry:
Publication Number
WO/2024/260434
Publication Date
26.12.2024
International Application No.
PCT/CN2024/100524
International Filing Date
21.06.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR)
[French]
COMPOSITIONS ET PROCÉDÉS POUR INHIBER L'EXPRESSION DE LA 3-HYDROXY-3-MÉTHYLGLUTARYL-COA RÉDUCTASE (HMGCR)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
XIA, Shiwei
Priority Data
PCT/CN2023/101548
21.06.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4576 | |
| EPO | Filing, Examination, Granting | 63493 | |
| Japan | Filing, Examination, Granting | 3973 | |
| South Korea | Filing, Examination, Granting | 5940 | |
| USA | Filing, Examination, Granting | 22240 |
Total:
100,222
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Compositions and methods useful to reduce expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene and for treatment of HMGCR-associated diseases and conditions. HMGCR dsRNA agents, HMGCR antisense polynucleotide agents, compositions comprising HMGCR dsRNA agents, and compositions comprising HMGCR antisense polynucleotide agents that can be used to reduce HMGCR expression in cells and subjects.[French]
L'invention concerne des compositions et des procédés utiles pour réduire l'expression du gène 3-hydroxy-3-méthylglutaryl-CoA réductase (HMGCR) et pour le traitement de maladies et d'états pathologiques associés à HMGCR. L'invention concerne également des agents ARNdb HMGCR, des agents polynucléotidiques antisens HMGCR, des compositions comprenant des agents ARNdb HMGCR, et des compositions comprenant des agents polynucléotidiques antisens HMGCR qui peuvent être utilisés pour réduire l'expression de HMGCR dans des cellules et chez des sujets.